B.R.I.D.G.E. TO DATA is a unique one-stop for all databases you might need for any research purpose. A unique user-friendly directory to search for databases from all over the world, you can easily grasp what each database can offer you without wasting time on each one.
We are excited to introduce the Norwegian Surveillance System for Communicable Diseases as our 400th profile. Established in 1975, the system relies on the reporting of infectious diseases from healthcare providers and laboratories across the country. The data collected are used to develop public health policies, monitor disease trends, and respond to outbreaks.
2022 had us busy profiling databases from around the world (currently 400), including the first ones from six countries. We made several enhancements and also lowered the “global” subscription rate to make our resource more affordable to locate databases of interest. Would you complete our 2-minute survey regarding how you could benefit from B.R.I.D.G.E.?
Christina Bergland
Executive Director, Division of Health Data and Digitalisation
Norwegian Institute of Public Health
NORWAY
Email: Christine.Bergland@fhi.no
For data access, send an email to datatilgang@fhi.no
General contact information for MSIS -
Phone: (+47) 2107 7000
1. Tipu JH, Sivertsen A, Afset JE, Sandven L, Brekke H, Lund HM, Elburg LS, Gaustad P, Lier T, Tverelv LR, Johansen ØH. Cryptosporidium species and subtypes in Norway: predominance of C. parvum and emergence of C. mortiferum. Emerging Microbes & Infections. 2024 Dec 31;13(1):2412624.
2. Tunheim G, Fossum E, Robertson AH, Rø GØ, Chopra A, Vaage JT, Vikse EL, Kran AM, Magnus P, Trogstad L, Mjaaland S. Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults. BMC Infectious Diseases. 2024 Aug 20;24(1):841.
3. Trinh NT, Houghtaling J, Bernal FL, Hayati S, Maglanoc LA, Lupattelli A, Halvorsen L, Nordeng HM. Harmonizing Norwegian registries onto OMOP common data model: Mapping challenges and opportunities for pregnancy and COVID-19 research. International Journal of Medical Informatics. 2024 Aug 14:105602.
4. Salamanca BV, Cyr PR, Bentdal YE, Watle SV, Wester AL, Strand ÅM, Bøås H. Increase in invasive group A streptococcal infections (iGAS) in children and older adults, Norway, 2022 to 2024. Eurosurveillance. 2024 May 16;29(20):2400242.
5. Jore S, Viljugrein H, Hjertqvist M, Dub T, Mäkelä H. Outdoor recreation, tick borne encephalitis incidence and seasonality in Finland, Norway and Sweden during the COVID-19 pandemic (2020/2021). Infection Ecology & Epidemiology. 2023 Dec 31;13(1):2281055.
6. Hetlevik Ø, Wensaas KA, Baste V, Emberland KE, Özgümüs T, Håberg SE, Rortveit G. Prevalence and predictors of post-COVID-19 symptoms in general practice-a registry-based nationwide study. BMC Infectious Diseases. 2023 Oct 25;23(1):721.
7. Gravningen K, Nymark P, Wyller TB, Kacelnik O. A new automated national register-based surveillance system for outbreaks in long-term care facilities in Norway detected three times more severe acute respiratory coronavirus virus 2 (SARS-CoV-2) clusters than traditional methods. Infection Control & Hospital Epidemiology. 2023 Sep;44(9):1451-7.
8. Whittaker R, Toikkanen S, Dean K, Lyngstad TM, Buanes EA, Kløvstad H, Paulsen TH, Seppälä E. A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022. Eurosurveillance. 2023 Aug 17;28(33):2200888.
9. Caspersen IH, Trogstad L, Galanti MR, Karvonen S, Peña S, Shaaban AN, Håberg SE, Magnus P. Current tobacco use and SARS-CoV-2 infection in two Norwegian population-based cohorts. BMC Public Health. 2023 May 10;23(1):846.
10. Skagseth H, Jørgensen SB, Reilly J, Kacelnik O. A new method for near real-time, nationwide surveillance of nosocomial COVID-19 in Norway: providing data at all levels of the healthcare system, March 2020 to March 2022. Eurosurveillance. 2023 Mar 23;28(12):2200493.
Starting in 1997, the Icelandic Register of Communicable Diseases includes diseases, agents causing diseases and events, immunisations, and use of antimicrobial drugs, and is intended to be of use in preventive measures and in epidemiological research. Notifiable communicable diseases which can pose a threat to public welfare are subject to registration.
Sigríður Haralds Elínardóttir
Head of Division, Health Information
Directorate of Health
Katrínartún 2
IS – 105 Reykjavík
ICELAND
Phone: +354 510 1900
Email: sigridur.haraldsd.elinardottir@landlaeknir.is
https://island.is/en/o/directorate-of-health/contact-the-directorate-of-health
N/A
Academia / Nonprofits / Government agencies always get a discounted rate, as do companies that let us profile their population healthcare databases/registries in our resource. In addition, if you sign up for Unlimited Users worldwide for 2 or more years, you can receive a 10% discount (pre-paid)! Finally, licensing our B.R.I.D.G.E.
With registrations starting back in 1948, the National Cancer Registration and Analysis Service (NCRAS) is run by the National Disease Registration Service (NDRS) which is part of NHS England. It is responsible for cancer registration in England to support cancer epidemiology, public health, service monitoring and research. NCRAS is responsible for systematic collection of data about cancer and tumour diseases in England.
Sarah Stevens
Associate Director for NDRS
(National Disease Registration Service)
Email: sarah.stevens1@nhs.net
N/A
1. White BE, Russell B, Remmers S, Rous B, Chandrakumaran K, Wong KF, Van Hemelrijck M, Srirajaskanthan R, Ramage JK. Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012-2018: A Retrospective, Population-Based Study. Cancers (Basel). 2023 Mar 20;15(6):1863.
2. Sundar S, Nordin A, Morrison J, Wood N, Ghaem-Maghami S, Nieto J, Phillips A, Butler J, Burton K, Gornall R, Dobbs S, Glasspool R, Peevor R, Ledermann J, McNeish I, Ratnavelu N, Duncan T, Frost J, Lim K, Michael A, Brockbank E, Gajjar K, Taylor A, Bowen R, Andreou A, Ganesan R, Nicum S, Edmondson R, Clayton R, Balega J, Rolland P, Maxwell H, Fotopoulou C. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer. Cancers (Basel). 2023 Jan 4;15(2):337.
3. Paisey SA, Weerasuriya S, Palmer K, White BE, Srirajaskanthan R, Chandrakumaran K, Ramage JK. Primary renal neuroendocrine neoplasms: A systematic literature review, report of four local cases, and original survival analysis of 63 patients from a national registry 2012-2018. J Neuroendocrinol. 2022 Dec;34(12):e13215.
4. M A, S C, J F, C L, A B, L P, Sj S. Incidence and Outcome of Breast Sarcomas in England (2013-2018): An analysis from the National Cancer Registration and Analysis Service. Eur J Cancer. 2022 Oct;174:48-56.
5. White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, George G, Russell B, Srirajaskanthan R, Ramage JK. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study. Lancet Reg Health Eur. 2022 Sep 23;23:100510.
6. Aggarwal A, Han L, van der Geest S, Lewis D, Lievens Y, Borras J, Jayne D, Sullivan R, Varkevisser M, van der Meulen J. Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study. Lancet Oncol. 2022 Sep;23(9):1211-1220.
7. Ng OH, Lunevicius R, Arthur JD. Rising incidence of colorectal cancer in individuals younger than 50 years and increasing mortality from rectosigmoid cancer in England. Colorectal Dis. 2021 Oct;23(10):2637-2646.
8. Wanis HA, Møller H, Ashkan K, Davies EA. The incidence of major subtypes of primary brain tumors in adults in England 1995-2017. Neuro Oncol. 2021 Aug 2;23(8):1371-1382.
9. Lai J, Mak V, Bright CJ, Lyratzopoulos G, Elliss-Brookes L, Gildea C. Reviewing the impact of 11 national Be Clear on Cancer public awareness campaigns, England, 2012 to 2016: A synthesis of published evaluation results. Int J Cancer. 2021 Mar 1;148(5):1172-1182.
10. Burton A, Tataru D, Driver RJ, Bird TG, Huws D, Wallace D, Cross TJS, Rowe IA, Alexander G, Marshall A; HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep. 2021 Jan 19;3(2):100232.
